Impact of Duodenal-Jejunal Exclusion on Satiety Hormones

C. de Jonge, Sander S. Rensen, Froukje Verdam, R.P. Vincent, S.R. Bloom, Wim A. Buurman, C.W. le Roux, Nicole D. Bouvy, J.W. Greve*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

65 Downloads (Pure)

Abstract

OBJECTIVE: Bariatric procedures that exclude the proximal small intestine lead to significant weight loss which is probably mediated by changes in hormones that alter appetite, such as peptide YY (PYY), ghrelin, cholecystokinin (CCK), and leptin. Here, the effect of the non-surgical duodenal-jejunal bypass liner (DJBL) on concentrations of hormones implicated in appetite control was investigated. SUBJECTS: A two-center prospective study was conducted between January and December 2010. Seventeen obese subjects with type 2 diabetes were treated with the DJBL for 24 weeks. Fasting concentrations of leptin and meal responses of plasma PYY, CCK, and ghrelin were determined prior to and after implantation of the DJBL. RESULTS: At baseline, subjects had an average body weight of 116.0 +/- 5.8 kg. One week after implantation, subjects had lost 4.3 +/- 0.6 kg (p < 0.01), which progressed to 12.7 +/- 1.3 kg at week 24 (p < 0.01). Postprandial concentrations of PYY and ghrelin increased (baseline vs. week 1 vs. week 24 PYY: 2.6 +/- 0.2 vs. 4.1 +/- 0.4 vs. 4.1 +/- 0.7 nmol/L/min and ghrelin: 7.8 +/- 1.8 vs. 11.0 +/- 1.8 vs. 10.6 +/- 1.8 ng/mL/min, all p < 0.05). In parallel, the CCK response decreased (baseline vs. week 1 vs. week 24: 434 +/- 51 vs. 229 +/- 52 vs. 256 +/- 51pmol/L/min, p < 0.01). Fasting leptin concentrations also decreased (baseline vs. week 24: 98 +/- 17 vs. 53 +/- 10 ng/mL, p < 0.01). CONCLUSIONS: DJBL treatment induces weight loss paralleled by changes in concentrations of hormones involved in appetite control.
Original languageEnglish
Pages (from-to)672-678
Number of pages7
JournalObesity Surgery
Volume26
Issue number3
DOIs
Publication statusPublished - Mar 2016

Keywords

  • Satiety
  • Bariatric surgery
  • Obesity
  • Gut hormones
  • Y GASTRIC BYPASS
  • GLUCAGON-LIKE PEPTIDE-1
  • BARIATRIC SURGERY
  • WEIGHT-LOSS
  • OBESE SUBJECTS
  • GUT HORMONES
  • BODY-WEIGHT
  • GASTROINTESTINAL HORMONES
  • FOOD-INTAKE
  • CARDIOVASCULAR RISK

Cite this